查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1468145

2024-2032 年按产品、测试类型、流感类型、最终用户和地区分類的流感诊断市场报告

Influenza Diagnostics Market Report by Product, Test Type, Type of Flu, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球流感诊断市场规模达到 9.52 亿美元。疫苗接种工作的不断增加、即时检测的便利性、流感病毒研究的不断增加以及透过公共卫生计划提高认识是推动市场发展的一些因素。

流行性感冒，俗称流感，是一种主要针对呼吸系统的病毒感染，包括鼻子、喉咙和肺部。流感诊断包括一系列免疫测定测试，旨在识别呼吸道样本中是否存在甲型和乙型流感病毒核蛋白抗原。可用的诊断选项包括快速抗原检测、逆转录聚合酶链反应 (RT-PCR)、免疫萤光测定、血清学和快速分子测定。医学界依靠这些测试来及时检测流感株并对其进行分类，以帮助做出有效的治疗决策和公共卫生管理。诊断技术的不断发展和对流感病毒的持续研究提高了这些测试的效率和可靠性。在医疗保健提供者努力应对季节性流感爆发和潜在流行病的同时，准确的诊断仍然是基石，可以实现快速干预和明智的医疗策略。

全球市场主要是由流感爆发的增加所推动的。与此一致的是，全球对潜在流行病日益增长的担忧推动了对诊断能力的投资，为市场做出了巨大贡献。此外，快速的技术创新提高了诊断测试的准确性和速度，对市场产生了积极影响。除此之外，日益增多的公众意识活动鼓励更多的人及时进行检测，从而刺激了市场。此外，不断增加的医疗保健支出支持先进诊断方法的采用，推动了市场的发展。此外，老年人更容易感染严重流感，这增加了对诊断的需求。此外，城市人口的增加导致感染率上升，需要强有力的诊断。频繁的旅行会加速流感的传播，因此需要有效的诊断。这反过来又为市场提供了众多机会。

流感诊断市场趋势/驱动因素：

轻鬆获得医疗保健

轻鬆获得医疗保健正在刺激市场成长。改善医疗设施的可近性鼓励个人及时寻求流感感染的诊断检测。当医疗服务很容易获得时，人们更倾向于在症状出现时接受检测，从而儘早发现并采取适当的干预措施。这种及时的方法不仅有助于防止病毒传播，而且有助于改善患者的治疗效果。此外，便捷的医疗设施支援采用各种诊断方法，包括即时检测，无需大量实验室基础设施即可快速获得结果。这种便利的医疗保健环境为诊断製造商、医疗保健提供者和患者创造了有利的生态系统，最终促进市场成长。

多种慢性病盛行率上升

几种慢性疾病的日益流行正在刺激市场。糖尿病、心血管疾病和呼吸系统疾病等慢性疾病会削弱免疫系统，使人更容易受到严重流感感染。随着受这些慢性病影响的人数增加，对准确和早期流感诊断的需求不断增加。慢性病患者出现流感併发症的风险较高，因此需要及时检测并采取量身定制的医疗干预措施。医疗保健提供者优先对这些弱势群体进行检测，以减轻潜在的併发症并提供及时的治疗。此外，慢性病和流感之间的相互关联性凸显了综合诊断方法的必要性。对已有疾病的个体进行准确的流感诊断使医疗保健专业人员能够制定治疗计划、有效管理併发症并改善患者的治疗效果。随着慢性病在全球持续增加，对流感诊断的需求成为保障患有基础疾病的个人健康不可或缺的一部分。这种持续的需求对市场做出了巨大贡献。

人工智慧快速融合

人工智慧（AI）的快速融合正在对市场产生积极影响。人工智慧技术透过提高流感检测的准确性、速度和效率，正在彻底改变诊断能力。人工智慧驱动的演算法可以分析来自各种来源的大量资料，包括患者病史、症状和测试结果，以提供更精确和客製化的诊断见解。这加速了流感病例的识别，从而能够及时采取医疗干预措施和公共卫生应对措施。机器学习和人工智慧演算法也改进了流感爆发的预测模型。透过分析历史资料、模式和环境因素，这些技术有助于预测潜在的流感流行，帮助医疗机构有效地准备和分配资源。此外，人工智慧驱动的影像分析有助于评估胸部 X 光片等医学影像，以识别流感相关併发症并准确监测疾病进展。人工智慧整合的快速发展正在改变诊断格局，为医疗保健专业人员提供先进的工具，以实现更明智的决策和精确的患者护理。这种趋势对市场贡献很大。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球流感诊断市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 检测试剂盒和试剂
    • 市场走向
    • 市场预测
  • 仪器
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按测试类型

  • 分子诊断测试
    • 市场走向
    • 关键环节
      • 聚合酶炼式反应
      • 等温核酸扩增试验
      • 其他分子测试
    • 市场预测
  • 传统诊断测试
    • 市场走向
    • 关键环节
      • 快速流感诊断测试
      • 病毒培养测试
      • 直接萤光抗体测试
      • 血清学测试
    • 市场预测

第 8 章：市场区隔：依流感类型

  • A型流感
    • 市场走向
    • 市场预测
  • B 型流感
    • 市场走向
    • 市场预测
  • C型流感
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 诊断实验室
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Coris Bioconcept
    • Danaher Corporation
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd (Roche Holding AG)
    • Hologic Inc.
    • Meridian Bioscience Inc.
    • Qiagen NV
    • Quidel Corporation
    • Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
    • Siemens Healthineers AG (Siemens AG)
Product Code: SR112024A6053

The global influenza diagnostics market size reached US$ 952.0 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,594.0 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032. The increasing vaccination efforts, the convenience of point-of-care tests, the rising research into flu viruses, and the growing awareness through public health programs are some of the factors propelling the market.

Influenza, commonly known as the flu, is a viral infection primarily targeting the respiratory system, encompassing the nose, throat, and lungs. Influenza diagnostics encompasses an array of immunoassay tests designed to identify the presence of influenza A and B viral nucleoprotein antigens within respiratory samples. Among the diagnostic options available are rapid antigen testing, reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assays, serology, and rapid molecular assays. The medical fraternity relies on these tests to detect and categorize influenza strains promptly, aiding in effective treatment decisions and public health management. The continual evolution of diagnostic techniques and the ongoing research into influenza viruses enhance the efficiency and reliability of these tests. As healthcare providers strive to combat seasonal flu outbreaks and potential pandemics, accurate diagnostics remain a cornerstone, enabling swift intervention and informed medical strategies.

The global market is majorly driven by the increasing occurrence of flu outbreaks. In line with this, the rising global concerns about potential pandemics drive investments in diagnostic capabilities, significantly contributing to the market. Furthermore, rapid technological innovations improve the accuracy and speed of diagnostic tests, positively influencing the market. Apart from this, the growing public awareness campaigns encourage more individuals to seek timely testing, catalyzing the market. Moreover, the escalating healthcare spending supports the adoption of advanced diagnostic methods, propelling the market. Besides, elderly individuals are more susceptible to severe flu, boosting demand for diagnostics. Additionally, the increasing urban populations contribute to higher infection rates, requiring robust diagnostics. Frequent travel accelerates the spread of the flu, necessitating efficient diagnostics. This, in turn, offers numerous opportunities for the market.

Influenza Diagnostics Market Trends/Drivers:

Easy access to healthcare

The easy access to healthcare is stimulating market growth. Improved accessibility to medical facilities encourages individuals to seek timely diagnostic testing for flu infections. When healthcare services are easily reachable, people are more inclined to undergo testing at the onset of symptoms, leading to early detection and appropriate intervention. This timely approach not only aids in preventing the spread of the virus but also facilitates better patient outcomes. Furthermore, convenient access to healthcare facilities supports the adoption of various diagnostic methods, including point-of-care testing, which provides rapid results without requiring extensive laboratory infrastructure. This accessible healthcare environment creates a favorable ecosystem for diagnostic manufacturers, healthcare providers, and patients, ultimately contributing to market growth.

Increasing prevalence of several chronic diseases

The increasing prevalence of several chronic diseases is catalyzing the market. Chronic diseases, such as diabetes, cardiovascular disorders, and respiratory conditions, weaken the immune system and make individuals more susceptible to severe flu infections. As the number of individuals affected by these chronic conditions rises, the demand for accurate and early influenza diagnostics intensifies. Patients with chronic diseases are at a higher risk of complications from the flu, necessitating prompt detection and tailored medical interventions. Healthcare providers prioritize testing these vulnerable populations to mitigate potential complications and provide timely treatment. Moreover, the interconnectedness of chronic diseases and flu underscores the need for comprehensive diagnostic approaches. Accurate flu diagnosis in individuals with pre-existing conditions enables healthcare professionals to tailor treatment plans, manage complications effectively, and improve patient outcomes. As chronic diseases continue to increase globally, the demand for influenza diagnostics becomes integral in safeguarding the health of individuals with underlying conditions. This ongoing demand significantly contributes to the market.

Rapid integration of artificial intelligence

The rapid integration of artificial intelligence (AI) is favorably impacting the market. AI technologies are revolutionizing diagnostic capabilities by enhancing flu detection accuracy, speed, and efficiency. AI-powered algorithms can analyze vast amounts of data from various sources, including patient histories, symptoms, and test results, to provide more precise and tailored diagnostic insights. This accelerates the identification of flu cases, enabling timely medical interventions and public health responses. Machine learning and AI algorithms also improve predictive modeling for flu outbreaks. By analyzing historical data, patterns, and environmental factors, these technologies aid in forecasting potential flu epidemics, assisting healthcare organizations in preparing and allocating resources effectively. Additionally, AI-driven image analysis assists in evaluating medical images, such as chest X-rays, to identify flu-related complications and monitor disease progression accurately. The rapid pace of AI integration is transforming the diagnostic landscape, offering healthcare professionals advanced tools for more informed decision-making and precise patient care. This trend contributes significantly to the market.

Influenza Diagnostics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, test type, type of flu and end user.

Breakup by Product:

Test Kit and Reagents

Instruments

Others

Test Kit and Reagents dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes test kit and reagents, instruments, and others. According to the report, test kit and reagents represented the largest segment.

Test kit and reagents form the foundation of diagnostic procedures, providing the necessary chemical components for identifying viral antigens and antibodies in patient samples. These kits enable healthcare professionals to swiftly and accurately diagnose influenza infections, facilitating timely medical interventions and public health responses. The continuous innovation in test kit technology, including improved sensitivity and specificity, contributes to heightened accuracy in flu detection.

On the other hand, instruments encompass the equipment for processing and analyzing samples, automating diagnostic workflows, and delivering reliable results. These instruments, ranging from PCR machines to automated immunoassay platforms, streamline the testing process, reduce human errors, and enhance the overall efficiency of diagnostics.

Breakup by Test Type:

Molecular Diagnostic Tests

Polymerase Chain Reaction

Isothermal Nucleic Acid Amplification Tests

Other Molecular Tests

Traditional Diagnostic Tests

Rapid Influenza Diagnostic Tests

Viral Culture Tests

Direct Fluorescent Antibody Test

Serological Tests

Traditional Diagnostic Test dominates the market

The report has provided a detailed breakup and analysis of the market based on the test type. This includes molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests, other molecular tests) and traditional diagnostic tests (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests). According to the report, traditional diagnostic tests represented the largest segment.

Traditional diagnostic tests encompass methods like rapid antigen testing and immunofluorescence assays. While they may not offer the same level of sensitivity as molecular tests, they provide rapid results, making them invaluable in scenarios where swift diagnosis is critical for patient management and public health responses.

Molecular diagnostic tests on the other hand, utilize advanced molecular techniques such as polymerase chain reaction (PCR) and nucleic acid amplification to detect the influenza virus's genetic material directly. These tests offer high sensitivity and specificity, enabling early and accurate identification of viral infections. The increasing adoption of molecular diagnostic tests is driven by their ability to detect multiple flu strains and their potential to differentiate between seasonal and novel influenza viruses.

Breakup by Type of Flu:

Type A Flu

Type B Flu

Type C Flu

Type A Flu dominates the market

The report has provided a detailed breakup and analysis of the market based on the type of flu. This includes type A flu, type B flu, and type C flu. According to the report, type A flu represented the largest segment.

"Type A Flu" includes various influenza viruses, some responsible for seasonal flu outbreaks and potential pandemics. Accurate differentiation of specific Type A strains is essential for targeted treatment and surveillance efforts.

Furthermore, "Type B Flu" encompasses a distinct group of viruses contributing to seasonal flu epidemics. Detecting and categorizing Type B strains aid in tailoring medical interventions and vaccine development to mitigate flu-related complications.

Moreover, "Type C Flu," although typically milder, still requires accurate diagnosis for effective patient management. While it is less likely to cause large outbreaks, its inclusion highlights the comprehensive approach to influenza diagnostics.

Breakup by End User:

Hospitals

Diagnostic Laboratories

Others

Hospitals dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostic laboratories, and others. According to the report, hospitals represented the largest segment.

Hospitals encompass a significant portion of the market demand, offering immediate access to diagnostic services for patients with flu-like symptoms. Timely diagnosis within hospitals enables rapid treatment decisions and infection control measures, which are crucial for managing patient health and preventing virus spread within healthcare facilities.

Furthermore, diagnostic Laboratories are specialized hubs for accurate and thorough flu testing. These laboratories often employ advanced equipment and experienced personnel to conduct comprehensive diagnostic procedures. By focusing on high-quality diagnostics, they support healthcare providers in delivering accurate results, essential for effective patient management and public health interventions.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America's emphasis on research and innovation fosters the development of cutting-edge diagnostic technologies and methodologies. This region leads in adopting advanced testing solutions that enhance the accuracy and efficiency of flu detection. Its high prevalence of chronic diseases and respiratory conditions underscores the need for accurate influenza diagnostics. With a focus on timely detection, healthcare providers in North America rely on a wide range of diagnostic tests to ensure prompt treatment and prevent escalating flu-related complications.

Government initiatives, awareness campaigns, and strong healthcare policies drive the demand for influenza diagnostics. The region's robust public health infrastructure emphasizes the importance of accurate diagnostics in managing seasonal outbreaks and potential pandemics. The prevalence of international travel and globalization also heightens the demand for accurate flu testing in North America, as early detection becomes crucial in preventing the importation and spread of viral strains. The region's commitment to accurate and timely diagnostics positions it as a key driver in shaping the industry's expansion.

Competitive Landscape:

Top companies are bolstering the market through their innovative approaches and expertise. These companies leverage their resources and research capabilities to drive market expansion. They invest significantly in research and development, leading to the creation of advanced diagnostic technologies. These innovations, including AI-powered platforms and rapid testing solutions, enhance the accuracy and efficiency of flu detection. Top companies collaborate with healthcare providers and institutions to ensure widespread product access. These partnerships facilitate the integration of cutting-edge diagnostic solutions into existing healthcare systems, expanding market reach. Moreover, these companies often conduct awareness campaigns to educate healthcare professionals and the public about the importance of timely flu testing. These efforts drive increased demand for accurate diagnostics. Furthermore, their global presence and distribution networks enable them to provide essential diagnostic tools to regions with varying levels of healthcare infrastructure, contributing to overall market growth.

The report has provided a comprehensive analysis of the competitive landscape in the influenza diagnostics market. Detailed profiles of all major companies have also been provided.

Abbott Laboratories

Becton Dickinson and Company

Coris Bioconcept

Danaher Corporation

DiaSorin S.p.A.

F. Hoffmann-La Roche Ltd (Roche Holding AG)

Hologic Inc.

Meridian Bioscience Inc.

Qiagen N.V

Quidel Corporation

Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)

Siemens Healthineers AG (Siemens AG).

Recent Developments:

In August 2020, Abbott launched the BinaxNOW COVID-19 Ag Card, a rapid antigen test for detecting SARS-CoV-2, the virus causing COVID-19.

In August 2020, BD received Emergency Use Authorization from the FDA for a rapid point-of-care antigen test to detect SARS-CoV-2, providing results in 15 minutes.

In April 2020, Cepheid, a subsidiary of Danaher, received FDA Emergency Use Authorization for its Xpert Xpress SARS-CoV-2 test, designed to deliver rapid results for detecting COVID-19.

Key Questions Answered in This Report

  • 1. What was the size of the global influenza diagnostics market in 2023?
  • 2. What is the expected growth rate of the global influenza diagnostics market during 2024-2032?
  • 3. What are the key factors driving the global influenza diagnostics market?
  • 4. What has been the impact of COVID-19 on the global influenza diagnostics market?
  • 5. What is the breakup of the global influenza diagnostics market based on the product?
  • 6. What is the breakup of the global influenza diagnostics market based on the test type?
  • 7. What is the breakup of the global influenza diagnostics market based on type of flu?
  • 8. What is the breakup of the global influenza diagnostics market based on the end user?
  • 9. What are the key regions in the global influenza diagnostics market?
  • 10. Who are the key players/companies in the global influenza diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Test Kit and Reagents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Test Type

  • 7.1 Molecular Diagnostic Tests
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction
      • 7.1.2.2 Isothermal Nucleic Acid Amplification Tests
      • 7.1.2.3 Other Molecular Tests
    • 7.1.3 Market Forecast
  • 7.2 Traditional Diagnostic Tests
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Rapid Influenza Diagnostic Tests
      • 7.2.2.2 Viral Culture Tests
      • 7.2.2.3 Direct Fluorescent Antibody Test
      • 7.2.2.4 Serological Tests
    • 7.2.3 Market Forecast

8 Market Breakup by Type of Flu

  • 8.1 Type A Flu
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Type B Flu
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Type C Flu
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Coris Bioconcept
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 DiaSorin S.p.A.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd (Roche Holding AG)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Meridian Bioscience Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Qiagen N.V
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Quidel Corporation
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Siemens Healthineers AG (Siemens AG)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Influenza Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Diagnostics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Influenza Diagnostics Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Influenza Diagnostics Market: Breakup by Test Type (in %), 2023
  • Figure 6: Global: Influenza Diagnostics Market: Breakup by Type of Flu (in %), 2023
  • Figure 7: Global: Influenza Diagnostics Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Influenza Diagnostics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Influenza Diagnostics (Test Kit and Reagents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Influenza Diagnostics (Test Kit and Reagents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Influenza Diagnostics (Instruments) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Influenza Diagnostics (Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Influenza Diagnostics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Influenza Diagnostics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Influenza Diagnostics (Molecular Diagnostic Tests) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Influenza Diagnostics (Molecular Diagnostic Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Influenza Diagnostics (Traditional Diagnostic Tests) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Influenza Diagnostics (Traditional Diagnostic Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Influenza Diagnostics (Type A Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Influenza Diagnostics (Type A Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Influenza Diagnostics (Type B Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Influenza Diagnostics (Type B Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Influenza Diagnostics (Type C Flu) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Influenza Diagnostics (Type C Flu) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Influenza Diagnostics (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Influenza Diagnostics (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Influenza Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Influenza Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Influenza Diagnostics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Influenza Diagnostics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia-Pacific: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia-Pacific: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Influenza Diagnostics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: Influenza Diagnostics Market: Breakup by Country (in %), 2023
  • Figure 79: Middle East and Africa: Influenza Diagnostics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Influenza Diagnostics Industry: SWOT Analysis
  • Figure 81: Global: Influenza Diagnostics Industry: Value Chain Analysis
  • Figure 82: Global: Influenza Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Diagnostics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Influenza Diagnostics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Influenza Diagnostics Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 4: Global: Influenza Diagnostics Market Forecast: Breakup by Type of Flu (in Million US$), 2024-2032
  • Table 5: Global: Influenza Diagnostics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Influenza Diagnostics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Influenza Diagnostics Market: Competitive Structure
  • Table 8: Global: Influenza Diagnostics Market: Key Players